Remains on Track for Full and Final FDA Approval
for U.S. Manufactured Implants
Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical
aesthetics company, today announced its financial results for the
fourth quarter and full year ended December 31, 2017.
Jeffrey M. Nugent, Chairman and Chief Executive
Officer of Sientra, said, “I am proud of our team’s accomplishments
through 2017 that helped Sientra’s progress to become a leading
global aesthetics company. Sientra’s base portfolio has been
strengthened through diversification and is showing traction in all
categories as a result of our continued strong relationships and
credibility within our targeted professional sectors. We have
completed the majority of the requirements needed for full FDA
approval of our breast implant products. Our site-change PMA
supplement and two of three smaller submissions for manufacturing
process improvements have been approved and shortened the timeline
to our relaunch into the breast implant market. We look forward to
begin selling our U.S. manufactured silicone gel breast implants
and offering our customers and their patients with the
well-documented Sientra advantages.”
“As it relates to the final outstanding PMA
submission, we provided the FDA with our comprehensive response in
late February and have been working interactively with the Agency
to gain final approval. Though statutorily the FDA has
until the middle of the second quarter of 2018 to respond to the
one remaining submission, we continue to believe the questions
raised by the FDA should be resolvable before then based
on encouraging dialogue over these past few weeks. Finally, on a
separate regulatory topic, I am pleased to announce our ISO 13485
certification has been granted. This incremental ISO certification
represents a significant milestone as it will allow Sientra to
enter select international markets with compelling comparative
clinical data as the 3rd FDA-approved portfolio of breast implants
available OUS.”
Mr. Nugent added, “The acquisition of Miramar
Labs, now renamed miraDry, completed in the third quarter of 2017
has significantly strengthened the Sientra portfolio. Through the
integration into Sientra, we have attracted a larger group of
highly experienced individuals into our commercial organization
both domestically and internationally. We have also made a number
of improvements to the clinical protocol resulting in positive
feedback on treatment efficacy that heightened professional
interest and market awareness. Overall, improvements since the
acquisition have further validated our confidence in our unique
opportunity to deliver a proven long term solution to a significant
number of patients with unmet needs.”
Patrick F. Williams, Chief Financial Officer of
Sientra, said, “Following our recent shelf registration and
subsequent filing of an At-The-Market equity feature, we believe
that we have a high degree of financial flexibility with a number
of options to strengthen our capital structure. We look forward to
having access to an additional $10 million from our existing credit
facility upon full and final FDA manufacturing approval and believe
that our capital options and associated economics become more
favorable upon approval.”
Fourth Quarter 2017 Financial
Review
As of the third quarter 2017, the Company has
reported results in two segments, Breast Products and miraDry. The
Breast Products segment includes the Company’s breast implant
portfolio, tissue expander portfolio, and scar management products.
The miraDry segment consists of the miraDry business, the
acquisition of which was completed on July 25, 2017.
Total net sales for the fourth quarter 2017 were
$11.1 million, compared to total net sales of $6.5 million for the
same period in 2016. Total net sales for the year ended December
31, 2017 were $36.5 million, compared to total net sales of $20.7
million for the full year 2016.
Net sales for the Breast Products segment
totaled $8.2 million in the fourth quarter 2017, a 26% increase
compared to $6.5 million for fourth quarter 2016, driven primarily
by the continued strong performance of the Company’s breast tissue
expanders, particularly the Allox2 dual port product line. For the
full year 2017, net sales of the Breast Products increased 52% to
$31.5 million from $20.7 million in the prior year period.
Net sales for the miraDry segment totaled $2.9
million in the fourth quarter 2017, and $5.1 million for the full
year.
Gross profit for the fourth quarter 2017 was
$5.3 million, or 48% of sales, compared to gross profit of $3.9
million, or 61% of sales, for the same period in 2016. Gross profit
for the full year 2017 was $22.4 million, or 61% of sales, compared
to gross profit of $13.9 million, or 67% of sales, for the full
year 2016. The decrease in gross profit margin for both the quarter
and year is primarily due to the inclusion of miraDry, which
carries a lower margin than Breast Products, and an increase in
excess and obsolete inventory reserve in our Breast Products
segment.
Operating expenses for the fourth quarter 2017
were $22.7 million, up 89% from $12.0 million for the same period
in 2016. Full year 2017 operating expenses were $85.3 million, up
58% from $53.9 million in 2016. Operating expenses in the fourth
quarter 2017 were driven higher primarily due to the increase in
employee related costs and the inclusion of miraDry operating
expenses subsequent to the acquisition.
Net loss for the fourth quarter 2017 was ($17.8)
million, compared to ($8.1) million for the same period in 2016.
Overall, the net loss for the year ending December 31, 2017 was
($64.0) million, compared to ($40.2) million in 2016.
On a non-GAAP basis, the Company reported
adjusted EBITDA loss of ($14.2) million for the fourth quarter
2017, compared to an adjusted EBITDA loss of ($7.0) million for the
fourth quarter 2016. For the full year 2017, adjusted EBITDA loss
was ($42.1) million, versus ($35.6) million in the previous
year.
Net cash and cash equivalents as of December 31,
2017 were $26.6 million compared to $37.6 million at the end of the
third quarter 2017.
Additional information on the Company’s
financial results can be found in Sientra’s Supplemental Financial
and Operational Information schedule by visiting the Investor
Relations section of Sientra’s website at www.sientra.com.
Conference Call
Sientra will hold a conference call
today, Tuesday, March 13, 2018 at 1:30 p.m. PT/4:30
p.m. ET to discuss the results.
The dial-in numbers are (844) 464-3933 for
domestic callers and (765) 507-2612 for international callers. The
conference ID is 3166619. A live webcast of the conference
call will be available on the Investor Relations section of the
Company's website at www.sientra.com.
Use of Pro Forma & Non-GAAP
Financial Measures
Sientra has supplemented its US GAAP net
sales and net loss with a Pro Forma net sales and non-GAAP measure
of Adjusted EBITDA. Management believes that these Pro Forma and
non-GAAP financial measures provide useful supplemental information
to management and investors regarding the performance of the
Company, facilitates a more meaningful comparison of results for
current periods with previous operating results, and assists
management in analyzing future trends, making strategic and
business decisions and establishing internal budgets and forecasts.
Tables showing Pro Forma net sales and a reconciliation of non-GAAP
Adjusted EBITDA to GAAP net loss, the most directly comparable GAAP
measure, are provided in the schedules below.
There are limitations in using non-GAAP
financial measures because they are not prepared in accordance with
GAAP and may be different from non-GAAP financial measures used by
other companies. These non-GAAP financial measures should not be
considered in isolation or as a substitute for GAAP financial
measures. Investors and potential investors should consider
non-GAAP financial measures only in conjunction with Sientra’s
financial statements prepared in accordance with GAAP and the
reconciliations of the non-GAAP financial measures provided in the
schedules below.
About Sientra
Headquartered in Santa Barbara, California,
Sientra is a medical aesthetics company committed to making a
difference in patients’ lives by enhancing their body image,
growing their self-esteem and restoring their confidence. The
Company was founded to provide greater choice to board-certified
plastic surgeons and patients in need of medical aesthetics
products. The Company has developed a broad portfolio of products
with technologically differentiated characteristics, supported by
independent laboratory testing and strong clinical trial outcomes.
The Company sells its breast implants and breast tissue expanders
exclusively to board-certified and board-admissible plastic
surgeons and tailors its customer service offerings to their
specific needs. The Company also offers a range of other aesthetic
and specialty products including BIOCORNEUM®, the professional
choice in scar management, and miraDry, the only FDA cleared device
to reduce underarm sweat, odor and permanently reduce hair of all
colors.
Forward Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
based on management’s current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and actual
results may differ materially from those expressed or implied in
such statements due to numerous risks and uncertainties.
Forward-looking statements include, but are not limited to,
statements regarding the timing of FDA approval of the Company’s
new manufacturing facility, the expected benefits of the miraDry
acquisition, the Company’s ability to become a world class,
diversified aesthetics organization, and the timing of the
re-launch of the Company’s breast implants. Such statements are
subject to risks and uncertainties, including the dependence on
positive reaction from plastic surgeons and their patients and
risks associated with contracting with any third-party manufacturer
and supplier, including uncertainties that a PMA Supplement or
other regulatory requirements will be timely approved by the FDA or
other applicable regulatory authorities and that the integration of
recently acquired product lines will not achieve the anticipated
benefits. Additional factors that could cause actual results
to differ materially from those contemplated in this press release
can be found in the Risk Factors section of Sientra’s most recently
filed Annual Report on Form 10-K for the year ended December 31,
2017. All statements other than statements of historical fact
are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’
‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’
‘‘continue,’’ ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements.
Estimates, projections and other forward-looking statements speak
only as of the date they were made, and, except to the extent
required by law, the Company undertakes no obligation to update or
review any estimate, projection or forward-looking statement.
Investor Contacts:Patrick F. WilliamsSientra,
Chief Financial Officer (619)
675-1047patrick.williams@sientra.com
Tram Bui / Brian JohnstonThe Ruth Group(646)
536-7035 / (646) 536-7028ir@sientra.com
|
Sientra, Inc. |
Condensed Consolidated Statements of
Operations |
(In thousands, except per share and share
amounts) |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
December 31, |
|
December 31, |
|
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
Net sales |
|
$ |
11,065 |
|
|
$ |
6,488 |
|
|
$ |
36,542 |
|
|
$ |
20,734 |
|
Cost of goods sold |
|
|
5,744 |
|
|
|
2,561 |
|
|
|
14,171 |
|
|
|
6,880 |
|
Gross profit |
|
|
5,321 |
|
|
|
3,927 |
|
|
|
22,371 |
|
|
|
13,854 |
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Sales and
marketing |
|
|
12,810 |
|
|
|
4,074 |
|
|
|
33,911 |
|
|
|
20,607 |
|
Research and
development |
|
|
2,136 |
|
|
|
2,334 |
|
|
|
9,813 |
|
|
|
9,704 |
|
General and
administrative |
|
|
7,784 |
|
|
|
5,633 |
|
|
|
31,537 |
|
|
|
21,959 |
|
Legal settlement |
|
|
— |
|
|
|
— |
|
|
|
10,000 |
|
|
|
1,618 |
|
Total operating
expenses |
|
|
22,730 |
|
|
|
12,041 |
|
|
|
85,261 |
|
|
|
53,888 |
|
Loss from
operations |
|
|
(17,409 |
) |
|
|
(8,114 |
) |
|
|
(62,890 |
) |
|
|
(40,034 |
) |
Other income (expense),
net: |
|
|
|
|
|
|
|
|
Interest income |
|
|
60 |
|
|
|
16 |
|
|
|
172 |
|
|
|
63 |
|
Interest expense |
|
|
(629 |
) |
|
|
20 |
|
|
|
(1,232 |
) |
|
|
(98 |
) |
Other income (expense),
net |
|
|
56 |
|
|
|
18 |
|
|
|
(95 |
) |
|
|
(36 |
) |
Total other income
(expense), net |
|
|
(513 |
) |
|
|
54 |
|
|
|
(1,155 |
) |
|
|
(71 |
) |
Loss before income
taxes |
|
|
(17,922 |
) |
|
|
(8,060 |
) |
|
|
(64,045 |
) |
|
|
(40,105 |
) |
Income tax (benefit)
expense |
|
|
(88 |
) |
|
|
13 |
|
|
|
(17 |
) |
|
|
61 |
|
Net loss |
|
$ |
(17,834 |
) |
|
$ |
(8,073 |
) |
|
$ |
(64,028 |
) |
|
$ |
(40,166 |
) |
Basic and diluted net
loss per share attributable to common stockholders |
|
$ |
(0.92 |
) |
|
$ |
(0.43 |
) |
|
$ |
(3.34 |
) |
|
$ |
(2.20 |
) |
Weighted average
outstanding common shares used for net loss per share
attributable to common stockholders: |
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
19,394,281 |
|
|
|
18,595,286 |
|
|
|
19,159,057 |
|
|
|
18,233,177 |
|
|
|
|
|
|
|
|
|
|
* The
results for the 3 and 12 months ended December 31, 2017 includes
miraDry as of the acquisition date of July 25, 2017 |
|
|
Sientra, Inc. |
Condensed Consolidated Balance
Sheets |
(In thousands) |
(Unaudited) |
|
|
|
|
|
|
|
December 31, |
|
December 31, |
|
|
|
2017 |
|
|
2016 |
Assets |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash
equivalents |
|
$ |
26,588 |
|
$ |
67,212 |
Accounts receivable,
net |
|
|
6,569 |
|
|
3,082 |
Inventories, net |
|
|
20,896 |
|
|
18,484 |
Insurance recovery
receivable |
|
|
39 |
|
|
9,375 |
Prepaid expenses and
other current assets |
|
|
1,473 |
|
|
1,852 |
Total current
assets |
|
|
55,565 |
|
|
100,005 |
Property and equipment,
net |
|
|
4,763 |
|
|
2,986 |
Goodwill |
|
|
12,507 |
|
|
4,878 |
Other intangible
assets, net |
|
|
18,803 |
|
|
6,186 |
Other assets |
|
|
575 |
|
|
228 |
Total assets |
|
$ |
92,213 |
|
$ |
114,283 |
Liabilities and
Stockholders’ Equity |
|
|
|
|
Current
liabilities: |
|
|
|
|
Current portion of
long-term debt |
|
$ |
24,639 |
|
$ |
— |
Accounts payable |
|
|
5,811 |
|
|
3,555 |
Accrued and other
current liabilities |
|
|
13,474 |
|
|
6,507 |
Legal settlement
payable |
|
|
1,000 |
|
|
10,900 |
Customer deposits |
|
|
5,423 |
|
|
6,559 |
Total current
liabilities |
|
|
50,347 |
|
|
27,521 |
Deferred and contingent
consideration |
|
|
12,597 |
|
|
1,637 |
Warranty reserve and
other long-term liabilities |
|
|
1,646 |
|
|
1,508 |
Total liabilities |
|
|
64,590 |
|
|
30,666 |
Stockholders’
equity: |
|
|
|
|
Total stockholders’
equity |
|
|
27,623 |
|
|
83,617 |
Total liabilities and
stockholders’ equity |
|
$ |
92,213 |
|
$ |
114,283 |
|
|
|
|
|
|
|
|
Sientra, Inc. |
Condensed Consolidated Statements of Cash
Flows |
(In thousands) |
(Unaudited) |
|
|
Year Ended |
|
|
December 31, |
|
|
|
2017 |
|
|
|
2016 |
|
Cash flows from
operating activities: |
|
|
|
|
Net
loss |
|
$ |
(64,028 |
) |
|
$ |
(40,166 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
Depreciation and amortization |
|
|
3,034 |
|
|
|
1,177 |
|
Provision
for doubtful accounts |
|
|
493 |
|
|
|
437 |
|
Provision
for warranties |
|
|
294 |
|
|
|
71 |
|
Provision
for inventory |
|
|
3,125 |
|
|
|
1,323 |
|
Amortization of acquired inventory step-up |
|
|
999 |
|
|
|
61 |
|
Change in
fair value of warrants |
|
|
95 |
|
|
|
39 |
|
Change in
fair value of deferred and contingent consideration |
|
|
1,025 |
|
|
|
37 |
|
Non-cash
portion of debt extinguishment loss |
|
|
17 |
|
|
|
— |
|
Amortization of debt discount and issuance costs |
|
|
140 |
|
|
|
— |
|
Non-cash
interest expense |
|
|
1 |
|
|
|
3 |
|
Stock-based compensation expense |
|
|
6,766 |
|
|
|
3,236 |
|
Loss on
disposal of property and equipment |
|
|
25 |
|
|
|
124 |
|
Deferred
income taxes |
|
|
(21 |
) |
|
|
61 |
|
Changes
in assets and liabilities, net of effects from acquisitions: |
|
|
|
|
Accounts
receivable |
|
|
(1,890 |
) |
|
|
927 |
|
Inventories |
|
|
527 |
|
|
|
2,390 |
|
Prepaid
expenses, other current assets and other assets |
|
|
674 |
|
|
|
(529 |
) |
Insurance
recovery receivable |
|
|
9,336 |
|
|
|
(9,375 |
) |
Accounts
payable |
|
|
1,290 |
|
|
|
(564 |
) |
Accrued
and other liabilities |
|
|
3,218 |
|
|
|
(1,422 |
) |
Legal
settlement payable |
|
|
(9,900 |
) |
|
|
10,900 |
|
Customer
deposits |
|
|
(1,136 |
) |
|
|
(3,160 |
) |
Net cash
used in operating activities |
|
|
(45,916 |
) |
|
|
(34,430 |
) |
Cash flows from
investing activities: |
|
|
|
|
Purchase
of property and equipment |
|
|
(1,864 |
) |
|
|
(1,126 |
) |
Business
acquisitions, net of cash acquired |
|
|
(18,455 |
) |
|
|
(11,709 |
) |
Net cash
used in investing activities |
|
|
(20,319 |
) |
|
|
(12,835 |
) |
Cash flows from
financing activities: |
|
|
|
|
Proceeds
from exercise of stock options |
|
|
1,346 |
|
|
|
923 |
|
Proceeds
from issuance of common stock under ESPP |
|
|
647 |
|
|
|
753 |
|
Tax
payments related to shares withheld for vested restricted stock
units (RSUs) |
|
|
(725 |
) |
|
|
— |
|
Gross
borrowings under the Term Loan |
|
|
25,000 |
|
|
|
— |
|
Gross
borrowings under the Revolving Line of Credit |
|
|
5,000 |
|
|
|
— |
|
Payment
on the Revolving Line of Credit |
|
|
(5,000 |
) |
|
|
— |
|
Deferred
financing costs |
|
|
(657 |
) |
|
|
— |
|
Net cash
provided by financing activities |
|
|
25,611 |
|
|
|
1,676 |
|
Net
decrease in cash and cash equivalents |
|
|
(40,624 |
) |
|
|
(45,589 |
) |
Cash and cash
equivalents at: |
|
|
|
|
Beginning
of period |
|
|
67,212 |
|
|
|
112,801 |
|
End of
period |
|
$ |
26,588 |
|
|
$ |
67,212 |
|
|
|
|
|
|
Supplemental disclosure
of cash flow information: |
|
|
|
|
Interest
paid |
|
$ |
870 |
|
|
$ |
96 |
|
Supplemental disclosure
of non-cash investing and financing activities: |
|
|
|
|
Property
and equipment in accounts payable and accrued liabilities |
|
|
1,088 |
|
|
|
939 |
|
Acquisition of business, deferred and contingent consideration
obligations at fair value |
|
|
10,912 |
|
|
|
1,600 |
|
Forgiveness of SVB Loan commitment fee |
|
|
750 |
|
|
|
— |
|
Accrued
deferred financing costs |
|
|
6 |
|
|
|
— |
|
|
|
|
|
|
* The
results for the 12 months ended December 31, 2017 includes miraDry
as of the acquisition date of July 25, 2017 |
|
|
Sientra, Inc. |
Reconciliation of Net Loss to Non-GAAP
Adjusted EBITDA |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
December 31, |
|
December 31, |
Dollars, in
thousands |
|
|
2017 |
|
|
|
2016 |
|
|
|
2017 |
|
|
|
2016 |
|
Net Loss, as
reported |
|
$ |
(17,834 |
) |
|
$ |
(8,073 |
) |
|
$ |
(64,028 |
) |
|
$ |
(40,166 |
) |
Adjustments to net
loss: |
|
|
|
|
|
|
|
|
Interest (income)
expense and other, net |
|
|
513 |
|
|
|
(54 |
) |
|
|
1,155 |
|
|
|
71 |
|
Provision for income
taxes |
|
|
(88 |
) |
|
|
13 |
|
|
|
(17 |
) |
|
|
61 |
|
Depreciation and
amortization - COGS |
|
|
294 |
|
|
|
61 |
|
|
|
1,141 |
|
|
|
61 |
|
Depreciation and
amortization - G&A |
|
|
707 |
|
|
|
342 |
|
|
|
2,321 |
|
|
|
935 |
|
Depreciation and
amortization - S&M |
|
|
55 |
|
|
|
33 |
|
|
|
161 |
|
|
|
110 |
|
Depreciation and
amortization - R&D |
|
|
138 |
|
|
|
68 |
|
|
|
410 |
|
|
|
132 |
|
Stock-based
compensation |
|
|
1,989 |
|
|
|
606 |
|
|
|
6,766 |
|
|
|
3,236 |
|
Legal settlement
expense |
|
|
- |
|
|
|
- |
|
|
|
10,000 |
|
|
|
- |
|
Total Adjustments to
net loss |
|
|
3,608 |
|
|
|
1,069 |
|
|
|
21,937 |
|
|
|
4,606 |
|
Adjusted EBITDA |
|
$ |
(14,226 |
) |
|
$ |
(7,004 |
) |
|
$ |
(42,091 |
) |
|
$ |
(35,560 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Twelve Months Ended |
|
|
|
December 31, |
|
December 31, |
|
As a Percentage
of Revenue** |
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
|
Net Loss, as
reported |
|
(161.2 |
%) |
|
(124.4 |
%) |
|
(175.2 |
%) |
|
(193.7 |
%) |
|
Adjustments to net
loss: |
|
|
|
|
|
|
|
|
|
Interest (income)
expense and other, net |
|
4.6 |
% |
|
(0.8 |
%) |
|
3.2 |
% |
|
0.3 |
% |
|
Provision for income
taxes |
|
(0.8 |
%) |
|
0.2 |
% |
|
(0.0 |
%) |
|
0.3 |
% |
|
Depreciation and
amortization - COGS |
|
2.7 |
% |
|
0.9 |
% |
|
3.1 |
% |
|
0.3 |
% |
|
Depreciation and
amortization - G&A |
|
6.4 |
% |
|
5.3 |
% |
|
6.4 |
% |
|
4.5 |
% |
|
Depreciation and
amortization - S&M |
|
0.5 |
% |
|
0.5 |
% |
|
0.4 |
% |
|
0.5 |
% |
|
Depreciation and
amortization - R&D |
|
1.2 |
% |
|
1.0 |
% |
|
1.1 |
% |
|
0.6 |
% |
|
Stock-based
compensation |
|
18.0 |
% |
|
9.3 |
% |
|
18.5 |
% |
|
15.6 |
% |
|
Legal settlement
expense |
|
0.0 |
% |
|
0.0 |
% |
|
27.4 |
% |
|
0.0 |
% |
|
Total Adjustments to
net loss |
|
32.6 |
% |
|
16.5 |
% |
|
60.0 |
% |
|
22.2 |
% |
|
Adjusted EBITDA |
|
(128.6 |
%) |
|
(108.0 |
%) |
|
(115.2 |
%) |
|
(171.5 |
%) |
|
|
|
|
|
|
|
|
|
|
|
* The
results for the 3 and 12 months ended December 31, 2017 includes
miraDry as of the acquisition date of July 25, 2017 |
**
Adjustments may not add to the total figure due to
rounding |
|
|
Sientra, Inc. |
Pro Forma Net Sales |
(Unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Year Ended |
|
|
December 31, |
|
December 31, |
Dollars, in
thousands |
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
Net sales - pro
forma |
|
$ |
11,065 |
|
$ |
10,899 |
|
$ |
46,747 |
|
$ |
41,179 |
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2023 to Apr 2024